Factors affecting immunodetection of hepatitis B surface antigen recombinant mutants

Akhtar Ali,Sandra Pearce,Paul Coleman
DOI: https://doi.org/10.1002/jmv.20970
IF: 20.693
2007-01-01
Journal of Medical Virology
Abstract:Immunoassays for hepatitis B surface antigen (HBsAg) capture antigen on a solid phase and then detect this immobilized antigen by a conjugate reagent that generates a signal. These capture and detection reagents can utilize either monoclonal antibody (single or multiple) or polyclonal antibodies or a combination of both. HBsAg capture and detection immunoreagents are usually directed against conformational epitopes of the “a” determinant. It is these same conformational epitopes that can be altered by mutations in HBsAg so that an immunoassay will return a false negative result if either the capture or detection immunoreagent is incapable of recognizing the viral mutant. The epitope recognition of capture or detection reagents is an important factor to consider when using an immunoassay to quantitate HBsAg mutants for use in testing panels. These quantitative concerns are compounded by our observation that production of recombinant HBsAg mutants can vary significantly in concentration when transfection variables are held constant. HBsAg mutant testing panels should be set at a concentration above the sensitivity endpoint of wildtype immunodetection so that a false negative due to reagent epitope recognition can be differentiated from a false negative due to assay sensitivity limitations. In this manner, recombinant HBsAg mutant panels can be used to estimate the ability of a particular immunoassay reagent configuration to detect altered HBsAg “a” determinant epitopes that may be encountered in actual clinical specimens. J. Med. Virol. 79:S47–S51, 2007. © 2007 Wiley‐Liss, Inc.
virology
What problem does this paper attempt to address?